Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is funded by PER®.

Emergence of HIF inhibitors in Renal Cell Carcinoma

Release Date: September 30, 2020
Expiration Date: September 30, 2021

Activity Overview

This continuing medical education (CME) activity is designed to inform health care providers involved in the clinical care of patients with renal cell carcinoma (RCC) of hypoxia inducible factor-2 alpha (HIF-2α) inhibition agents, a novel emerging class of therapies currently undergoing clinical evaluation for the treatment of these patients. The in-depth program will cover recent updates regarding clinical trials investigating HIF-2α inhibitors for RCC, including key data and their potential clinical implications for the therapeutic landscape of patients with RCC.

Acknowledgement of Commercial Support

This activity is funded by PER®.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the mechanism of action of HIF-2a inhibitors in renal cell carcinoma
  • Assess efficacy of HIF-2a inhibitors and how their application could affect the treatment landscape of renal cell carcinoma
  • Describe safety profiles of emerging HIF-2a inhibitors in renal cell carcinoma and strategies to mitigate adverse effects

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


David F. McDermott, MD
David F. McDermott, MD
Chief, Medical Oncology
Beth Israel Deaconess Medical Center
Boston, MA

Disclosures: Grant/Research Support: Bristol Myers Squibb, Merck & Co, Genentech, Pfizer, Exelixis, X4 Pharmaceuticals, Alkermes. Consultant: Bristol Myers Squibb, Pfizer, Merck & Co, Alkermes, EMD Serono, Eli Lilly & Company, Iovance Biotherapeutics, Eisai.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By